A vaccine that could provide a major breakthrough in the fight against Type 1 diabetes is to be tested in human trials.
Developed by Belgian biotech Imcyse, in collaboration with the French National Institute of Health and Medical Research (INSERM) in Paris – and 18 clinical sites across Europe, the company’s Imotopes™ technology can destroy immune cells that kill insulin-producing cells.